Infliximab for the treatment of Ipilimumab (anti CTLA-4) and Nivolumab/Pembrolizumab (anti PD-1) associated colitis

被引：0

作者：

Sidhu, M. ^{[1
]}

Mersaides, T. ^{[2
]}

Liniker, E. ^{[3
]}

Tate, D. ^{[1
]}

Long, G. ^{[3
]}

Nagrial, A. ^{[2
]}

Kariyawasam, V. ^{[4
]}

Sandanyake, N. ^{[5
]}

Kefford, R. ^{[2
]}

Carlino, M. ^{[2
]}

Kwan, V. ^{[1
]}

机构：

[1] Westmead Hosp, Dept Gastroenterol, Sydney, NSW, Australia

[2] Westmead Hosp, Crown Princess Mary Canc Inst, Sydney, NSW, Australia

[3] Melanoma Inst Australia, North Sydney, NSW, Australia

[4] Blacktown Hosp, Dept Gastroenterol, Sydney, NSW, Australia

[5] Royal N Shore Hosp, Dept Gastroenterol, Sydney, NSW, Australia

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2015年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：139 / 139

页数：1

共 50 条

[1] Infliximab for the Treatment of Ipilimumab (anti CTLA-4) and Nivolumab/Pembrolizumab (anti-PD-1) Associated Colitis
Sidhu, Mayenaaz
Mersaides, Antony
Liniker, Elizabeth
Tate, David J.
Nagrial, Adnan
Long, Georgina
Sandanayake, Neomal S.
Kariyawasam, Viraj C.
Carlino, Matteo S.
Kwan, Vu
[J]. GASTROENTEROLOGY, 2016, 150 (04) : S803 - S803
[2] Tolerance and Efficacy of Combined Nivolumab and Ipilimumab Following Monotherapy with PD-1 or CTLA-4 Blockade in Metastatic Melanoma
Randhawa, M.
Nguyen, B.
Ali, S.
Yip, D.
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 71 - 71
[3] Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
Minor, David R.
Chin, Kevin
Kashani-Sabet, Mohammed
[J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2009, 24 (03) : 321 - 325
[4] Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, Anand
[J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
[5] Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
[J]. Journal of Experimental & Clinical Cancer Research, 38
[6] Inhibiting CTLA-4 and PD-1 Boosts Response
不详
[J]. CANCER DISCOVERY, 2013, 3 (07) : 710 - 711
[7] Uveal consequences of CTLA-4 and PD-1 inhibition
Jager, Martine J.
[J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
[8] Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma
Santos-Briz, Angel
Canueto, Javier
Del Carmen, Sofia
Barrios, Beatriz
Yuste, Manuela
Bellido, Lorena
Dolores Ludena, Maria
Roman, Concepcion
[J]. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2021, 43 (06) : 423 - 428
[9] PD-1, CTLA-4 Point to Drug Response
Landhuis, Esther
[J]. CANCER DISCOVERY, 2016, 6 (11) : 1201 - 1201
[10] Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.
Mehmi, Inderjit
Hill, Jordan
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →